Recruiting

SUpport From PEeRs to Expand Access Study - Community

Investigators will evaluate the implementation of an evidence-based, Spanish-language, digital, cognitive-behavioral therapy (dCBT) intervention (SilverCloud) in the Mission community for Latino patients with depression and/or anxiety. 213 participants will be enrolled in a one-armed trial comparing self-guided vs. supported dCBT (SilverCloud).

ClinicalTrials.gov IDNCT07186816

PhaseNA

Enrollment213

SponsorUniversity of California, Berkeley

Age18 Years

SexALL

I'm interested View official listing

Conditions studied

Depression, Anxiety

About this study

Interventions

Device: Behavioral: Supported dCBT — In the supported dCBT condition, each patient will receive complete access to the SilverCloud platform. In addition, patients will be assigned a supporter who will provide regular support based on an established coaching support protocol. Supporters will conduct a brief engagement call (30-40 minutes) to provide an overview of SilverCloud, identify goals, and set expectations, introduce themselves, and orient the participant to the role of the peer supporter. Supporters will then provide weekly check-ins through phone calls or messaging. Participants will be able to communicate with the supporters through the platform through messaging or sharing activities for additional discussion. The major goal of the support is to promote use of the platform.
Device: Behavioral: Unsupported dCBT — Unsupported dCBT provides all features of the SilverCloud platform with the exception of support features (structured interactions with supporter and share features). Patients will be provided complete access to SilverCloud and instructed to use it for 8-weeks. Patients will receive weekly automated messages to encourage engagement.

Primary outcomes

Change in Depression at 8 Weeks (Change from Baseline to Week 8)
Change in Anxiety at 8 Weeks (Change from Baseline to Week 8)

Eligibility information

Inclusion Criteria: 1. PHQ-9 ≥ 10 or GAD-7 ≥ 8 2. Has access to the Internet via smartphone and/or broadband at home, and basic level of technological literacy or willingness to undergo a brief technology use training 3. ≥18 years of age 4. Preference for receiving medical care in Spanish 5. Not in concurrent psychotherapy 6. If currently taking an antidepressant medication, patient must have been on a stable dose for at least 6 weeks, and have no plans to change the dose. We will permit patients on antidepressants to enter the study, as this will increase generalizability. Antidepressant status will be monitored at each assessment to control for those effects, if necessary. Exclusion Criteria: 1. Currently receiving psychotherapy, as this treatment will be offered as a frontline treatment for depression and anxiety, however, patients are allowed to be referred to treatment while participating in this study and initiation of treatment will be monitored and considered in analyses 2. Visual, hearing, voice, or motor impairment or illiteracy that would prevent completion of study procedures 3. Diagnosis of a psychotic disorder, bipolar disorder, dissociative disorder, or substance use disorder 4. Severe suicidality (as assessed by expressing suicidal ideation, plan, and intent). Although procedures with back-up plans are in place for patients who develop suicidality (see Human Subjects Section), patients assessed with severe suicidality will be referred to more-intensive treatment resources.

Study locations

Zuckerberg San Francisco General, San Francisco, California 94110 United States

Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.

Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-09-27.